|
Herpes NOS
|
0.100 |
Biomarker
|
disease |
BEFREE |
Decoy receptor 3 (DcR3) competitively binds to Fas ligand, lymphotoxin-related inducible ligand that competes for glycoprotein D binding to herpes virus entry mediator on T cells (LIGHT) and TNF-like ligand 1A (TL1A), thereby preventing their effects.
|
28696795 |
2018 |
|
Herpes NOS
|
0.100 |
Biomarker
|
disease |
BEFREE |
We observed spontaneous osteoclastogenesis with a significant increase in OC formation and bone resorbing activity in late-stage CKD and HD patients when compared with early-stage CKD patients and healthy donors, likely due to an increased expression of RANKL and LIGHT (homologous to Lymphotoxins exhibiting Inducible expression and competing with herpes simplex virus Glycoprotein D for herpes virus entry mediator [HVEM], a receptor expressed by T lymphocytes) in PBMCs.
|
28992140 |
2018 |
|
Herpes NOS
|
0.100 |
Biomarker
|
disease |
BEFREE |
LIGHT (homologous to lymphotoxins, exhibiting inducible expression, and competing with herpes simplex virus (HSV) glycoprotein D for herpes virus entry mediator (HVEM), a receptor expressed by T lymphocytes) has been involved in various autoimmune and inflammatory disorders.
|
29952668 |
2018 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
Vaccine-induced antibodies to herpes simplex virus glycoprotein D epitopes involved in virus entry and cell-to-cell spread correlate with protection against genital disease in guinea pigs.
|
29791513 |
2018 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
LIGHT (homologous to lymphotoxins, exhibiting inducible expression, and competing with herpes simplex virus (HSV) glycoprotein D for herpes virus entry mediator (HVEM), a receptor expressed by T lymphocytes) has been involved in various autoimmune and inflammatory disorders.
|
29952668 |
2018 |
|
Herpes Simplex Infections
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We observed spontaneous osteoclastogenesis with a significant increase in OC formation and bone resorbing activity in late-stage CKD and HD patients when compared with early-stage CKD patients and healthy donors, likely due to an increased expression of RANKL and LIGHT (homologous to Lymphotoxins exhibiting Inducible expression and competing with herpes simplex virus Glycoprotein D for herpes virus entry mediator [HVEM], a receptor expressed by T lymphocytes) in PBMCs.
|
28992140 |
2018 |
|
White Blood Cell Count procedure
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Analyses of genome wide association data, cytokines, and gene expression in African-Americans with benign ethnic neutropenia.
|
29596498 |
2018 |
|
Blood Protein Measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genomic atlas of the human plasma proteome.
|
29875488 |
2018 |
|
Herpes NOS
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition to 3-<i>O</i>-sulfated HS, HSV-1 gD was reported to interact with other receptors, including herpes virus entry mediator (HVEM), nectin-1 and -2.
|
28174681 |
2017 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
The present study characterizes a therapeutic antitumor vaccine based on the genetic fusion of the Herpes simplex virus-1 (HSV-1) glycoprotein D (gD) with the E7 oncoprotein from HPV-16 (gDE7).
|
28522585 |
2017 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
Although the reaction of 3-O-sulfation can be catalysed by the largest family of HS sulfotransferases, very few mechanisms have been associated with this modification and to date, only glycoprotein D (gD) of herpes simplex virus-1 (HSV-1 gD) and cyclophilin B (CyPB) have been well-described as ligands for 3-<i>O</i>-sulfated HS.
|
28174681 |
2017 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
Herein, we report that the live-attenuated herpes simplex virus 1 (HSV-1) VC2 vaccine strain, which has been shown to be unable to enter into neurons and establish latency in mice, can be utilized as a vector for the heterologous expression of EHV-1 glycoprotein D (gD) and that the intramuscular immunization of mice results in strong antiviral humoral and cellular immune responses.
|
28404844 |
2017 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
A novel glycoprotein D-specific monoclonal antibody neutralizes herpes simplex virus.
|
29061442 |
2017 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
Evaluation of recombinant adenovirus vaccines based on glycoprotein D and truncated UL25 against herpes simplex virus type 2 in mice.
|
28378925 |
2017 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
Efficient production of recombinant glycoprotein D of herpes simplex virus type 2 in Pichia pastoris and its protective efficacy against viral challenge in mice.
|
27868164 |
2017 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
To investigate whether DNA vaccine encoding herpes simplex virus 1 (HSV-1) glycoprotein C (gC) and glycoprotein D (gD) will achieve better protective effect against herpes simplex keratitis (HSK) than DNA vaccine encoding gD alone.
|
29181304 |
2017 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
As specific RNA template, RNA extracted from stable transfectants ectopically expressing the herpes simplex virus 1 glycoprotein D gene was utilized.
|
28963576 |
2017 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
In summary, we found that monoclonal antibodies derived from humans vaccinated with the HVEM binding domain of HSV-1 gD (i) neutralized HSV-1 infection in a cell receptor-specific manner, (ii) mediated ADCC, and (iii) reduced ocular disease in virus-infected mice.<b>IMPORTANCE</b> Herpes simplex virus 1 (HSV-1) causes cold sores and neonatal herpes and is a leading cause of blindness.
|
28701403 |
2017 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
Mapping sites of herpes simplex virus type 1 glycoprotein D that permit insertions and impact gD and gB receptors usage.
|
28255168 |
2017 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
Herpes simplex virus glycoprotein D (gD) peptide at the N terminus of AIDSVAX<sup>®</sup> B/E and B/B gp120 proteins induced antibodies in all trials, although significantly higher in VAX trials. gD peptide induced IgA, IgG1, IgG2, and IgG3 but not IgG4.
|
28006952 |
2017 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
Previous studies focused on the herpes simplex virus (HSV) of the Simplexvirus genus, for which both the free gD structure and the gD/nectin-1 complex structure were reported at high resolutions.
|
28542478 |
2017 |
|
Herpes Simplex Infections
|
0.100 |
Biomarker
|
group |
BEFREE |
Herpesvirus entry mediator A (HVEM), nectin-1 and nectin-2 are cellular receptors of glycoprotein D (gD) of herpes simplex virus type-2 (HSV-2).
|
28671524 |
2017 |
|
White Blood Cell Count procedure
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genome-wide association of white blood cell counts in Hispanic/Latino Americans: the Hispanic Community Health Study/Study of Latinos.
|
28158719 |
2017 |
|
Neutrophil count (procedure)
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genome-wide association of white blood cell counts in Hispanic/Latino Americans: the Hispanic Community Health Study/Study of Latinos.
|
28158719 |
2017 |
|
Monocyte count procedure
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genome-wide association of white blood cell counts in Hispanic/Latino Americans: the Hispanic Community Health Study/Study of Latinos.
|
28158719 |
2017 |